Vertex Pharmaceuticals Stock

Vertex Pharmaceuticals Revenue 2024

Vertex Pharmaceuticals Revenue

10.97 B USD

Ticker

VRTX

ISIN

US92532F1003

WKN

882807

In 2024, Vertex Pharmaceuticals's sales reached 10.97 B USD, a 11.15% difference from the 9.87 B USD sales recorded in the previous year.

The Vertex Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e17.4649,28
2028e15.8354,36
2027e14.3559,98
2026e13.2465,00
2025e11.9871,87
2024e10.9778,46
20239.8787,21
20228.9387,90
20217.5788,06
20206.2188,14
20194.1686,84
20183.0586,56
20172.4989,04
20161.787,85
20151.0388,66
20140.5893,16
20131.2192,66
20121.5384,50
20111.4195,49
20100.14100,00
20090.1100,00
20080.184904,27
20070.24325,13
20060.223977,36
20050.165349,29
20040.18380,72

Vertex Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Vertex Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vertex Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vertex Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vertex Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vertex Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vertex Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vertex Pharmaceuticals’s growth potential.

Vertex Pharmaceuticals Revenue, EBIT and net profit per share

DateVertex Pharmaceuticals RevenueVertex Pharmaceuticals EBITVertex Pharmaceuticals Net Income
2029e17.46 B undefined0 undefined7.27 B undefined
2028e15.83 B undefined8.04 B undefined6.54 B undefined
2027e14.35 B undefined7.14 B undefined5.82 B undefined
2026e13.24 B undefined6.27 B undefined5.01 B undefined
2025e11.98 B undefined5.43 B undefined4.67 B undefined
2024e10.97 B undefined606.46 M undefined84.67 M undefined
20239.87 B undefined4.36 B undefined3.62 B undefined
20228.93 B undefined4.32 B undefined3.32 B undefined
20217.57 B undefined2.78 B undefined2.34 B undefined
20206.21 B undefined2.86 B undefined2.71 B undefined
20194.16 B undefined1.2 B undefined1.18 B undefined
20183.05 B undefined664 M undefined2.1 B undefined
20172.49 B undefined392.8 M undefined263.2 M undefined
20161.7 B undefined11.2 M undefined-112.1 M undefined
20151.03 B undefined-464.7 M undefined-556.3 M undefined
2014580.4 M undefined-641.5 M undefined-738.6 M undefined
20131.21 B undefined-156.6 M undefined-445 M undefined
20121.53 B undefined48.5 M undefined-107.4 M undefined
20111.41 B undefined221.7 M undefined29.3 M undefined
2010143.4 M undefined-694.6 M undefined-754.6 M undefined
2009101.9 M undefined-592.8 M undefined-642.2 M undefined
2008175.5 M undefined-458.4 M undefined-459.9 M undefined
2007199 M undefined-412.7 M undefined-391.3 M undefined
2006216.4 M undefined-225.3 M undefined-206.9 M undefined
2005160.9 M undefined-141.8 M undefined-203.4 M undefined
2004102.7 M undefined-137.2 M undefined-166.2 M undefined

Vertex Pharmaceuticals stock margins

The Vertex Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vertex Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vertex Pharmaceuticals.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vertex Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Vertex Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vertex Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vertex Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vertex Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vertex Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vertex Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vertex Pharmaceuticals Margin History

Vertex Pharmaceuticals Gross marginVertex Pharmaceuticals Profit marginVertex Pharmaceuticals EBIT marginVertex Pharmaceuticals Profit margin
2029e87.21 %0 %41.63 %
2028e87.21 %50.77 %41.33 %
2027e87.21 %49.77 %40.54 %
2026e87.21 %47.37 %37.8 %
2025e87.21 %45.31 %38.99 %
2024e87.21 %5.53 %0.77 %
202387.21 %44.17 %36.68 %
202287.9 %48.38 %37.2 %
202188.06 %36.73 %30.92 %
202088.14 %46.03 %43.7 %
201986.84 %28.77 %28.27 %
201886.56 %21.79 %68.79 %
201789.04 %15.78 %10.58 %
201687.85 %0.66 %-6.59 %
201588.66 %-45.02 %-53.89 %
201493.16 %-110.53 %-127.26 %
201392.66 %-12.92 %-36.72 %
201284.5 %3.18 %-7.03 %
201195.49 %15.72 %2.08 %
2010100 %-484.38 %-526.22 %
2009100 %-581.75 %-630.23 %
200887.21 %-261.2 %-262.05 %
200787.21 %-207.39 %-196.63 %
200687.21 %-104.11 %-95.61 %
200587.21 %-88.13 %-126.41 %
200487.21 %-133.59 %-161.83 %

Vertex Pharmaceuticals Aktienanalyse

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching, developing, and marketing therapies for rare diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA. Since its inception, Vertex has been dedicated to pushing the boundaries of science to develop groundbreaking therapies for diseases such as cystic fibrosis and other rare genetic disorders. The company's history began in 1989 when Joshua Boger, a former employee of Merck & Co., founded the company with the goal of becoming a leading developer of therapies for rare diseases. In 1993, Vertex went public, achieving significant success. In 2012, the company announced the development of the first approved therapy for the treatment of cystic fibrosis, Kalydeco. Since then, Vertex has expanded its technology and production capabilities and continues to work on developing additional therapies for rare genetic disorders. The business model of Vertex Pharmaceuticals Inc is based on researching and developing therapies for rare genetic disorders. The company collaborates closely with patients, leading scientists, and medical professionals to develop groundbreaking therapies. Vertex is a vertically integrated company, handling everything from research and development to production and marketing in-house. This allows the company to maintain control over the entire development and production process to ensure the highest quality products. Vertex is divided into different divisions to organize its activities. The Paris research facility specializes in the development of therapies for cystic fibrosis and other rare genetic disorders. The San Diego facility focuses on the development of treatments for cancer. Additionally, the company maintains research facilities in the UK and Canada. Vertex Pharmaceuticals Inc's most well-known product is Kalydeco, the first approved medication for the treatment of cystic fibrosis targeting a specific genetic mutation. Kalydeco aims to restore the function of a specific protein in the lungs, targeting the underlying cause of the disease. The company has also developed other therapies for cystic fibrosis, including Orkambi and Symdeko, which also target genetic mutations. Vertex also has therapies for cancer in its portfolio, such as the drug VX-970 currently in clinical trials for cancer treatment. In summary, Vertex Pharmaceuticals Inc is a leading biopharmaceutical company focused on developing therapies for rare genetic disorders. Since its founding in 1989, Vertex has continuously improved its technology and production capabilities, becoming one of the most innovative companies in the industry. The company is vertically integrated and consists of various research facilities dedicated to developing therapies for different diseases. Vertex has developed several groundbreaking medications for genetic disorders, including Kalydeco (the first approved medication for cystic fibrosis), Orkambi, and Symdeko. Vertex Pharmaceuticals Inc is an example of how research and development can play a significant role in treating rare diseases. Vertex Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Vertex Pharmaceuticals revenue by segment

In the annual report of the Vertex Pharmaceuticals share (US92532F1003, 882807, VRTX), it breaks down its revenues into 4 segments: 1. Symdeko, 2. Orkambi, 3. Kalydeco, 4. Trikafta. The Vertex Pharmaceuticals stock (WKN: 882807, ISIN: US92532F1003, Ticker Symbol: VRTX) is a leading investment for investors interested in participating in the Health Care sector.

  • 34 % Symdeko

  • 32 % Orkambi

  • 24 % Kalydeco

  • 10 % Trikafta

Revenue Details

Understanding Vertex Pharmaceuticals's Sales Figures

The sales figures of Vertex Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Vertex Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Vertex Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Vertex Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Vertex Pharmaceuticals stock

How much revenue did Vertex Pharmaceuticals generate this year?

Vertex Pharmaceuticals has achieved a revenue of 10.97 B USD this year.

How much was the turnover of the company Vertex Pharmaceuticals compared to the previous year?

The revenue of Vertex Pharmaceuticals has increased by 11.15% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Vertex Pharmaceuticals?

The revenue of Vertex Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Vertex Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Vertex Pharmaceuticals so important for investors?

The revenue of Vertex Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Vertex Pharmaceuticals pay?

Over the past 12 months, Vertex Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vertex Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Vertex Pharmaceuticals?

The current dividend yield of Vertex Pharmaceuticals is .

When does Vertex Pharmaceuticals pay dividends?

Vertex Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vertex Pharmaceuticals?

Vertex Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Vertex Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vertex Pharmaceuticals located?

Vertex Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vertex Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vertex Pharmaceuticals from 10/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/13/2024.

When did Vertex Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/13/2024.

What was the dividend of Vertex Pharmaceuticals in the year 2023?

In the year 2023, Vertex Pharmaceuticals distributed 0 USD as dividends.

In which currency does Vertex Pharmaceuticals pay out the dividend?

The dividends of Vertex Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Vertex Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Vertex Pharmaceuticals

Our stock analysis for Vertex Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vertex Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.